Petersen Drug Durable Medical Equipment & Medical Supplies Location: 302 Main St, Chadron, Nebraska 69337 Phone: (308) 432-2400 |
Walmart Pharmacy 10-2579 Durable Medical Equipment & Medical Supplies Location: 510 Linden St, Chadron, Nebraska 69337 Phone: (308) 432-6995 |
Safeway Pharmacy #2563 Durable Medical Equipment & Medical Supplies Location: 230 Morehead St, Chadron, Nebraska 69337 Phone: (308) 432-2070 |
News Archive
Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration for wilate (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease. The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare diseases.
When it comes to changing the way physicians practice, guidelines and educational initiatives alone are not effective. An editorial by James A. Arrighi, M.D., a cardiologist with Rhode Island Hospital, explains the effective methods to change physician behavior and improve compliance to guidelines. The editorial is published online in advance of print of the February 8 edition of the American Heart Association's journal Circulation.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
TrialReach, the world's largest provider of clinical trial information, today announced it has raised a $13.5M Series B financing round led by Smedvig Capital with participation from existing investors Amadeus Capital Partners and Octopus Investments. With one of the biggest digital health rounds ever raised in the United Kingdom, TrialReach plans to use the funds to support the growth of its clinical trial platform and expansion into the U.S..
Retinas from our earliest vertebrate ancestors had cone-like photoreceptors, presumably allowing them to see in daylight, but little ability to see at night. Then, millions of years ago in the Mesozoic era, and in relatively short order, mammals emerged that had retinas with predominantly rod photoreceptors, allowing for them to see at night perhaps to hunt for food while their dinosaur predators were dozing.
› Verified 2 days ago